SCHEMBL16772437

SCHEMBL16772437

CCCCCCC1c2ccc(C)cc2Oc2cc(OC)ccc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.40
GRM2 Q14416 3/20 0.39
CYP1A1 P04798 1/20 0.37
ALDH1A1 P00352 4/20 0.37
MAPT P10636 1/20 0.37
KDM4E B2RXH2 2/20 0.35
GAA P10253 2/20 0.35
HPGD P15428 2/20 0.35
HSD17B10 Q99714 2/20 0.35
USP2 O75604 1/20 0.35
GFER P55789 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ACHE P22303 1/20 0.35
MAOB P27338 1/20 0.34
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MIF P14174 1/20 0.33
NR3C1 P04150 1/20 0.33
TSHR P16473 1/20 0.33
PNLIP P16233 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31545446 1.00 HTR2A (0.40) HTR2AGRM2CYP1A1ALDH1A1MAPT
SCHEMBL16775323 0.93 HTR2A (0.44) HTR2AGRM2CYP1A1ALDH1A1MAPT
SCHEMBL31544986 0.82 MEN1 (0.40) GRM2MAPTUSP2TDP1TSHR
SCHEMBL20468642 0.82 MEN1 (0.40) GRM2MAPTUSP2TDP1TSHR
SCHEMBL20088338 0.76 CA12 (0.40) MAOBMIFTSHR
SCHEMBL6056694 0.76 HTR2A (0.45) HTR2AGRM2CYP1A1ALDH1A1MAPT
SCHEMBL16755695 0.74 TP53 (0.41) GRM2ALDH1A1MAPTKDM4EHSD17B10
SCHEMBL16772571 0.72 MAPKAPK2 (0.44) ALDH1A1MAPTKDM4EHPGDHSD17B10
SCHEMBL31545185 0.72 MAPKAPK2 (0.44) ALDH1A1MAPTKDM4EHPGDHSD17B10
SCHEMBL11829652 0.72 ALDH1A1 (0.37) HTR2AALDH1A1MAPTHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180222880-A1 SecA INHIBITORS AND METHODS OF MAKING AND USING THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-08-09 US disclosed
US-9957247-B2 SecA inhibitors and methods of making and using thereof GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2018-05-01 US disclosed
US-20150152077-A1 SecA Inhibitors and Methods of Making and Using Thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180222880-A1 SecA INHIBITORS AND METHODS OF MAKING AND USING THEREOF SEC61B, SEC61A1, SEC23A HTR2A 4675/4885GRM2 4822/4885CYP1A1 2833/4885
US-20150152077-A1 SecA Inhibitors and Methods of Making and Using Thereof SEC61B, SEC61A1, SEC23A HTR2A 4675/4885GRM2 4822/4885CYP1A1 2833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.